ACAD analyst estimates
Acadia Pharmaceuticals (ACAD) analyst ratings, the average price target and its range, and every firm's latest call.
ACAD analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Nov 5, 2026 | RBC Capital | Acadia Pharmaceuticals (ACAD) PT Raised to $38 at RBC Capital | $38.00 |
| Oct 13, 2026 | UBS | Acadia Pharmaceuticals downgraded to Neutral from Buy at UBS | $23.00 |
| Sep 28, 2026 | William Blair | Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at H.C. Wainwright | $33.00 |
| Sep 25, 2026 | Needham | Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at Needham | $35.00 |
| Sep 25, 2026 | BMO Capital | Acadia Pharmaceuticals price target lowered to $34 from $36 at BMO Capital | $34.00 |
| Sep 25, 2026 | Deutsche Bank | Acadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche Bank | $31.00 |
| Sep 25, 2026 | H.C. Wainwright | Acadia price target lowered to $33 from $37 at H.C. Wainwright | $33.00 |
| Aug 25, 2026 | Morgan Stanley | Acadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley | $28.00 |
| Aug 25, 2026 | Deutsche Bank | Acadia Pharmaceuticals price target raised to $38 from $37 at Deutsche Bank | $38.00 |
| Aug 17, 2026 | UBS | Acadia Pharmaceuticals price target raised to $49 from $45 at UBS | $49.00 |
| Aug 12, 2026 | Needham | Acadia Pharmaceuticals price target raised to $41 from $38 at Needham | $41.00 |
| Aug 10, 2026 | Morgan Stanley | Acadia Pharmaceuticals price target raised to $27 from $26 at Morgan Stanley | $27.00 |
| Aug 5, 2026 | Oppenheimer | Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Oppenheimer | $25.00 |
| Aug 5, 2026 | RBC Capital | Acadia Pharmaceuticals (ACAD) PT Raised to $37 at RBC Capital on 'Strong Sales' | $37.00 |
| Jul 29, 2026 | Raymond James | Acadia Pharmaceuticals (ACAD) PT Raised to $14.50 at BofA Securities | $14.50 |
- 16 firms rate ACAD: 12 buy, 4 hold, 0 sell.
- The average price target is $30.05 from None analysts, from $14.50 to $38.00.
Updated 2026-11-13 01:31 UTC